Guidance

Sickle cell and thalassaemia screening: antenatal failsafe procedures

This document explains the failsafe processes in antenatal screening for the NHS Sickle Cell and Thalassaemia Screening Programme.

• From: Public Health England
• Published: 1 May 2011
• Last updated: 16 March 2017 — See all updates

This publication was withdrawn on 16 March 2017

This publication has been superseded by guidance on checks and audits to improve quality and reduce risks.

Documents

NHS sickle cell and thalassaemia screening programme: failsafe processes

PDF, 1.34 MB, 10 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@phe.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

This document explains the antenatal failsafe processes for the Sickle Cell and Thalassaemia (SCT) Screening Programme.

Failsafe processes minimise the risks of anything going wrong in the screening pathway.

A separate document sets out the failsafe process for newborn screening.

Published 1 May 2011
Last updated 16 March 2017 + show all updates

1. 16 March 2017

   Archived publication.

2. 1 May 2011

   First published.